

### Listing of Claims

Claims 1-23 (Canceled).

Claim 24 (Currently Amended): A method of treating ~~or preventing~~ an inflammatory arthropathy in a subject comprising administering to a subject having an inflammatory arthropathy a therapeutically effective amount of ~~the oligodeoxynucleotide of claim 1a~~ a substantially pure or isolated oligodeoxynucleotide of 8 to 100 nucleotides in length, wherein (a) the oligodeoxynucleotide forms a G-tetrad; (b) the oligodeoxynucleotide has a CD value of greater than about 2.9; and (c) wherein the oligodeoxynucleotide comprises two to twenty TTAGGG motifs ~~to a subject having or at risk of developing an inflammatory arthropathy~~, thereby treating ~~or preventing~~ the inflammatory arthropathy.

Claim 25 (original): The method of claim 24, wherein the oligodeoxynucleotide is administered topically, parenterally, orally, intravenously, intra-muscularly, sub-cutaneously, or intra-articularly.

Claim 26 (original): The method of claim 24, wherein the oligodeoxynucleotide has a CD value of greater than about 3.0.

Claim 27 (original): The method of claim 24, wherein the oligodeoxynucleotide has a CD value of greater than about 3.2.

Claim 28 (Canceled).

Claim 29 (original): The method of claim 24, wherein the oligodeoxynucleotide is from about 10 to about 30 nucleotides in length.

Claim 30 (original): The method of claim 24, wherein the oligodeoxynucleotide comprises multiple guanosine-rich sequences.

Claim 31 (Canceled).

Claim 32 (original): The method of claim 24, wherein the oligodeoxynucleotide comprises from about two to about four guanosine-rich sequences.

Claim 33 (Currently Amended): The method of claim 24, wherein the oligodeoxynucleotide comprises four ~~at least one~~ TTAGGG motifs.

Claim 34 (Currently Amended): The method of claim 24, wherein the oligodeoxynucleotide comprises SEQ ID NO: 2 ~~multiple~~ TTAGGG motifs.

Claims 35-36 (canceled).

Claim 37 (original): The oligodeoxynucleotide of claim 24, wherein the oligodeoxynucleotide further comprises a CpG motif, and wherein at least one TTAGGG motif is 5' to the CpG motif.

Claim 38 (original): The oligodeoxynucleotide of claim 24, wherein the oligodeoxynucleotide further comprises a CpG motif, wherein the TTAGGG motif is 3' to the CpG motif, and wherein the TTAGGG motif is separated from the CpG motif by at least ten nucleotides.

Claim 39 (original): The method of claim 24, wherein the oligodeoxynucleotide comprises a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, and SEQ ID NO: 25.

Claim 40 (original): The method of claim 24, further comprising administering an additional anti-inflammatory, immunosuppressive, or anti-arthritis agent.

Claim 41 (original): The method of claim 40, wherein the agent is a biological response modifier, a disease-modifying antirheumatic drug, a steroid, a nonsteroidal anti-inflammatory drug, or a Cyclo-Oxygenase-2 inhibitor.

Claim 42 (original): The method of claim 40, wherein the agent is anakinra, etanercept, infliximab, leflunomide, prednisone, cortisone, celecoxib, choline magnesium trisalicylate, diclofenac, diclofenac potassium, diclofenac XR, diflunisal, etodolac, etodolac ER, fenoprofen, flurbiprofen oral, ibuprofen, indomethacin, indomethacin SR, indomethacin suppositories, ketoprofen, ketoprofen ER, meclofenamate, meloxicam, nabumetone, naproxen, naproxen CR, naproxen ER, oxaprozin, piroxicam, rofecoxib, salsalate, sulindac, or tolmetin sodium, hyaluronan, or hylan G-F20.

Claim 43 (Currently Amended): A method of treating ~~or preventing an~~ inflammatory ~~arthropathies~~ arthropathy in a subject comprising contacting immune cells with a therapeutically effective amount of ~~the oligodeoxynucleotide of claim 1~~ a substantially pure or isolated oligodeoxynucleotide of 8 to 100 nucleotides in length, wherein (a) the oligodeoxynucleotide forms a G-tetrad; (b) the oligodeoxynucleotide has a CD value of greater than about 2.9; and (c) wherein the oligodeoxynucleotide comprises two to twenty TTAGGG motifs, and transferring

the immune cells to a subject having ~~or at risk of developing inflammatory arthropathies~~  
arthropathy, thereby treating ~~or preventing the inflammatory arthropathies~~ arthropathy.

Claims 44-50 (canceled).

Claim 51 (New) The method of claim 24, wherein the oligodeoxynucleotide is modified to prevent degradation.

Claim 52 (New): The method of claim 51, wherein the oligodeoxynucleotide comprises a phosphate backbone modification.